IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection
Tuberculosis (TB) has huge impact on human morbidity and mortality and biomarkers to support rapid TB diagnosis and ensure treatment initiation and cure are needed, especially in regions with high prevalence of multi-drug resistant TB. Soluble interferon gamma inducible protein 10 (IP-10) analyzed f...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2015-03, Vol.5 (1), p.9223-9223, Article 9223 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9223 |
|---|---|
| container_issue | 1 |
| container_start_page | 9223 |
| container_title | Scientific reports |
| container_volume | 5 |
| creator | Tonby, Kristian Ruhwald, Morten Kvale, Dag Dyrhol-Riise, Anne Ma |
| description | Tuberculosis (TB) has huge impact on human morbidity and mortality and biomarkers to support rapid TB diagnosis and ensure treatment initiation and cure are needed, especially in regions with high prevalence of multi-drug resistant TB. Soluble interferon gamma inducible protein 10 (IP-10) analyzed from dry plasma spots (DPS) has potential as an immunodiagnostic marker in TB infection. We analyzed IP-10 levels in plasma directly and extracted from DPS in parallel by ELISA from 34 clinically well characterized patients with TB disease before and throughout 24 weeks of effective anti-TB chemotherapy. We detected a significant decline of IP-10 levels in both plasma and DPS already after two weeks of therapy with good correlation between the tests. This was observed both in pulmonary and extrapulmonary TB. In conclusion, plasma IP-10 may serve as an early biomarker for anti-TB chemotherapy responses and the IP-10 DPS method has potential to be developed into a point-of care test for use in resource-limited settings. Further studies must be performed to validate the use of IP-10 DPS in TB high endemic countries. |
| doi_str_mv | 10.1038/srep09223 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4363864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1664777651</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-f73a21ef6d6e6c00dc9ec1720f27966a8f1226ce0e31315eeefd008d83f27fab3</originalsourceid><addsrcrecordid>eNplkV9r1jAYxYMobsxd-AU04I0bdOZPm6Q3gkydg4kD53VI0ydbZpvUpBX67Zfxbi-vLjcJnB_nPE8OQq8pOaGEqw85wURaxvgztM9I3VSMM_Z8572HDnO-JeU0rK1p-xLtsUYq3spmH43nlxUleASTlwQ97lb8Oa34cjB5NPjnFOeMTcadj6NJvyFhFxOebyCZacUJ8hRDhox9wN9XGztjZ0h-GfHV0kGyyxCzv1cd2NnH8Aq9cGbIcPhwH6BfX79cnX6rLn6cnZ9-uqhsw9RcOckNo-BEL0BYQnrbgqWSEcdkK4RRjjImLBDglNMGAFxPiOoVL4AzHT9AHze-09KN0FsIczKDnpIvW6w6Gq__VYK_0dfxr6654ErUxeDtxsAmn2cfdIjJaEpUw3QtW8YL8f4hIsU_C-RZjz5bGAYTIC5ZUyFqKaVoaEHf_YfexiWF8gGaqlYJXjPVFuroMTLmUqrbjkuJvm9ab5su7Jvd_bbkY68FON4AuUjhGtJO5BO3O-7csqk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1898634289</pqid></control><display><type>article</type><title>IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection</title><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Tonby, Kristian ; Ruhwald, Morten ; Kvale, Dag ; Dyrhol-Riise, Anne Ma</creator><creatorcontrib>Tonby, Kristian ; Ruhwald, Morten ; Kvale, Dag ; Dyrhol-Riise, Anne Ma</creatorcontrib><description>Tuberculosis (TB) has huge impact on human morbidity and mortality and biomarkers to support rapid TB diagnosis and ensure treatment initiation and cure are needed, especially in regions with high prevalence of multi-drug resistant TB. Soluble interferon gamma inducible protein 10 (IP-10) analyzed from dry plasma spots (DPS) has potential as an immunodiagnostic marker in TB infection. We analyzed IP-10 levels in plasma directly and extracted from DPS in parallel by ELISA from 34 clinically well characterized patients with TB disease before and throughout 24 weeks of effective anti-TB chemotherapy. We detected a significant decline of IP-10 levels in both plasma and DPS already after two weeks of therapy with good correlation between the tests. This was observed both in pulmonary and extrapulmonary TB. In conclusion, plasma IP-10 may serve as an early biomarker for anti-TB chemotherapy responses and the IP-10 DPS method has potential to be developed into a point-of care test for use in resource-limited settings. Further studies must be performed to validate the use of IP-10 DPS in TB high endemic countries.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/srep09223</identifier><identifier>PMID: 25783975</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13 ; 13/21 ; 631/250/127/98 ; 692/308/1892 ; 692/53/2423 ; 692/699/255/1856 ; Adult ; Aged ; Aged, 80 and over ; Antitubercular Agents - therapeutic use ; Biomarkers - blood ; Chemokine CXCL10 - blood ; Chemotherapy ; Cohort Studies ; Dried Blood Spot Testing ; Drug resistance ; Enzyme-Linked Immunosorbent Assay ; Female ; Humanities and Social Sciences ; Humans ; IP-10 protein ; Male ; Middle Aged ; Morbidity ; multidisciplinary ; Multidrug resistance ; Mycobacterium tuberculosis - isolation & purification ; Mycobacterium tuberculosis - pathogenicity ; Plasma ; Science ; Tuberculosis ; Tuberculosis - diagnosis ; Tuberculosis - drug therapy ; Tuberculosis - microbiology</subject><ispartof>Scientific reports, 2015-03, Vol.5 (1), p.9223-9223, Article 9223</ispartof><rights>The Author(s) 2015</rights><rights>Copyright Nature Publishing Group Mar 2015</rights><rights>info:eu-repo/semantics/openAccess</rights><rights>Copyright © 2015, Macmillan Publishers Limited. All rights reserved 2015 Macmillan Publishers Limited. All rights reserved</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-f73a21ef6d6e6c00dc9ec1720f27966a8f1226ce0e31315eeefd008d83f27fab3</citedby><cites>FETCH-LOGICAL-c528t-f73a21ef6d6e6c00dc9ec1720f27966a8f1226ce0e31315eeefd008d83f27fab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363864/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363864/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,26565,27922,27923,41118,42187,51574,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25783975$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tonby, Kristian</creatorcontrib><creatorcontrib>Ruhwald, Morten</creatorcontrib><creatorcontrib>Kvale, Dag</creatorcontrib><creatorcontrib>Dyrhol-Riise, Anne Ma</creatorcontrib><title>IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Tuberculosis (TB) has huge impact on human morbidity and mortality and biomarkers to support rapid TB diagnosis and ensure treatment initiation and cure are needed, especially in regions with high prevalence of multi-drug resistant TB. Soluble interferon gamma inducible protein 10 (IP-10) analyzed from dry plasma spots (DPS) has potential as an immunodiagnostic marker in TB infection. We analyzed IP-10 levels in plasma directly and extracted from DPS in parallel by ELISA from 34 clinically well characterized patients with TB disease before and throughout 24 weeks of effective anti-TB chemotherapy. We detected a significant decline of IP-10 levels in both plasma and DPS already after two weeks of therapy with good correlation between the tests. This was observed both in pulmonary and extrapulmonary TB. In conclusion, plasma IP-10 may serve as an early biomarker for anti-TB chemotherapy responses and the IP-10 DPS method has potential to be developed into a point-of care test for use in resource-limited settings. Further studies must be performed to validate the use of IP-10 DPS in TB high endemic countries.</description><subject>13</subject><subject>13/21</subject><subject>631/250/127/98</subject><subject>692/308/1892</subject><subject>692/53/2423</subject><subject>692/699/255/1856</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Chemokine CXCL10 - blood</subject><subject>Chemotherapy</subject><subject>Cohort Studies</subject><subject>Dried Blood Spot Testing</subject><subject>Drug resistance</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>IP-10 protein</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>multidisciplinary</subject><subject>Multidrug resistance</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Mycobacterium tuberculosis - pathogenicity</subject><subject>Plasma</subject><subject>Science</subject><subject>Tuberculosis</subject><subject>Tuberculosis - diagnosis</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis - microbiology</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>3HK</sourceid><recordid>eNplkV9r1jAYxYMobsxd-AU04I0bdOZPm6Q3gkydg4kD53VI0ydbZpvUpBX67Zfxbi-vLjcJnB_nPE8OQq8pOaGEqw85wURaxvgztM9I3VSMM_Z8572HDnO-JeU0rK1p-xLtsUYq3spmH43nlxUleASTlwQ97lb8Oa34cjB5NPjnFOeMTcadj6NJvyFhFxOebyCZacUJ8hRDhox9wN9XGztjZ0h-GfHV0kGyyxCzv1cd2NnH8Aq9cGbIcPhwH6BfX79cnX6rLn6cnZ9-uqhsw9RcOckNo-BEL0BYQnrbgqWSEcdkK4RRjjImLBDglNMGAFxPiOoVL4AzHT9AHze-09KN0FsIczKDnpIvW6w6Gq__VYK_0dfxr6654ErUxeDtxsAmn2cfdIjJaEpUw3QtW8YL8f4hIsU_C-RZjz5bGAYTIC5ZUyFqKaVoaEHf_YfexiWF8gGaqlYJXjPVFuroMTLmUqrbjkuJvm9ab5su7Jvd_bbkY68FON4AuUjhGtJO5BO3O-7csqk</recordid><startdate>20150318</startdate><enddate>20150318</enddate><creator>Tonby, Kristian</creator><creator>Ruhwald, Morten</creator><creator>Kvale, Dag</creator><creator>Dyrhol-Riise, Anne Ma</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>3HK</scope><scope>5PM</scope></search><sort><creationdate>20150318</creationdate><title>IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection</title><author>Tonby, Kristian ; Ruhwald, Morten ; Kvale, Dag ; Dyrhol-Riise, Anne Ma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-f73a21ef6d6e6c00dc9ec1720f27966a8f1226ce0e31315eeefd008d83f27fab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>13</topic><topic>13/21</topic><topic>631/250/127/98</topic><topic>692/308/1892</topic><topic>692/53/2423</topic><topic>692/699/255/1856</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Chemokine CXCL10 - blood</topic><topic>Chemotherapy</topic><topic>Cohort Studies</topic><topic>Dried Blood Spot Testing</topic><topic>Drug resistance</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>IP-10 protein</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>multidisciplinary</topic><topic>Multidrug resistance</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Mycobacterium tuberculosis - pathogenicity</topic><topic>Plasma</topic><topic>Science</topic><topic>Tuberculosis</topic><topic>Tuberculosis - diagnosis</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tonby, Kristian</creatorcontrib><creatorcontrib>Ruhwald, Morten</creatorcontrib><creatorcontrib>Kvale, Dag</creatorcontrib><creatorcontrib>Dyrhol-Riise, Anne Ma</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database (ProQuest)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tonby, Kristian</au><au>Ruhwald, Morten</au><au>Kvale, Dag</au><au>Dyrhol-Riise, Anne Ma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2015-03-18</date><risdate>2015</risdate><volume>5</volume><issue>1</issue><spage>9223</spage><epage>9223</epage><pages>9223-9223</pages><artnum>9223</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Tuberculosis (TB) has huge impact on human morbidity and mortality and biomarkers to support rapid TB diagnosis and ensure treatment initiation and cure are needed, especially in regions with high prevalence of multi-drug resistant TB. Soluble interferon gamma inducible protein 10 (IP-10) analyzed from dry plasma spots (DPS) has potential as an immunodiagnostic marker in TB infection. We analyzed IP-10 levels in plasma directly and extracted from DPS in parallel by ELISA from 34 clinically well characterized patients with TB disease before and throughout 24 weeks of effective anti-TB chemotherapy. We detected a significant decline of IP-10 levels in both plasma and DPS already after two weeks of therapy with good correlation between the tests. This was observed both in pulmonary and extrapulmonary TB. In conclusion, plasma IP-10 may serve as an early biomarker for anti-TB chemotherapy responses and the IP-10 DPS method has potential to be developed into a point-of care test for use in resource-limited settings. Further studies must be performed to validate the use of IP-10 DPS in TB high endemic countries.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>25783975</pmid><doi>10.1038/srep09223</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2015-03, Vol.5 (1), p.9223-9223, Article 9223 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4363864 |
| source | MEDLINE; NORA - Norwegian Open Research Archives; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | 13 13/21 631/250/127/98 692/308/1892 692/53/2423 692/699/255/1856 Adult Aged Aged, 80 and over Antitubercular Agents - therapeutic use Biomarkers - blood Chemokine CXCL10 - blood Chemotherapy Cohort Studies Dried Blood Spot Testing Drug resistance Enzyme-Linked Immunosorbent Assay Female Humanities and Social Sciences Humans IP-10 protein Male Middle Aged Morbidity multidisciplinary Multidrug resistance Mycobacterium tuberculosis - isolation & purification Mycobacterium tuberculosis - pathogenicity Plasma Science Tuberculosis Tuberculosis - diagnosis Tuberculosis - drug therapy Tuberculosis - microbiology |
| title | IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T16%3A17%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IP-10%20measured%20by%20Dry%20Plasma%20Spots%20as%20biomarker%20for%20therapy%20responses%20in%20Mycobacterium%20Tuberculosis%20infection&rft.jtitle=Scientific%20reports&rft.au=Tonby,%20Kristian&rft.date=2015-03-18&rft.volume=5&rft.issue=1&rft.spage=9223&rft.epage=9223&rft.pages=9223-9223&rft.artnum=9223&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/srep09223&rft_dat=%3Cproquest_pubme%3E1664777651%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1898634289&rft_id=info:pmid/25783975&rfr_iscdi=true |